Cytrx Corp: (NASD: CYTR)

$2.43

0.01 (0.42%)

Volume 3,474

May 22 09:54 AM ET

Zacks Rank: 2-Buy

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		2.43 - 2.47
	
		52wk Low - High
		1.59 - 5.50
	
		Previous Close
		2.42
	
		Avg. Volume
		122,600
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		73.85 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.27
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-0.73
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		2
Buy

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		96 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/13/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.73
                        
                            Current Quarter Estimate
                            -0.14
                        
                            Most Accurate Estimate
                            -0.14
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-08-2013
                        
                            EPS Last Year
                            -0.93
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.   
Full CYTR Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
CYTR Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.14	-0.28	-0.73	-0.79
Number of Estimates	1	1	1	1
Low Estimate	-0.14	-0.28	-0.73	-0.79
High Estimate	-0.14	-0.28	-0.73	NA
Year Ago EPS	-0.22	-0.23	-0.90	-0.73
EPS Growth	36.36%	-21.74%	18.89%	-8.22%

More CYTR Estimates

Average Earnings Estimates for CYTR

EPS Growth for CYTR

Industry Analysis

Name	Symbol	Previous Close
CYTRX CORP	CYTR	2.42
AETERNA ZENTARS	AEZS	2.08
ANIKA THERAPEUT	ANIK	14.45
GENTIUM SPA-ADR	GENT	8.90
AASTROM BIOSCI	ASTM	0.57
ACHILLION PHARM	ACHN	7.75
ADDEX THERA LTD	ADDXF	6.94
AFFYMAX INC	AFFY	1.45
ALEXION PHARMA	ALXN	102.67
ALKERMES INC	ALKS	31.98

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Zacks #1 Rank Additions for Friday

Dec 14, 2012

Zacks #1 Rank Additions for Wednesday

Dec 12, 2012

Zacks #1 Rank Additions for Thursday

Nov 29, 2012

Zacks #1 Rank Additions for Tuesday

Nov 20, 2012

Report for CYTR

May 13, 2013

More CYTR Zacks Commentary

Financials

EPS TTM	-0.93
Sales	0
Net Income	-15
Price/Earnings	NA
Price/Book	3.13
Price/Cash Flow	NA
Price/Sales	NA

More CYTR Financials

News

CytRx Offers Initial Results from Trial with Aldoxorubicin in Solid Tumors - Benzinga

May 21, 2013

CytRx Offers Letter to Holders, Gives Business Update - Benzinga

May 20, 2013

CytRx Provides Update on Clinical Programs - Benzinga

May 8, 2013

Right Time To Buy This Pharmaceutical Company? - TheMotleyFool

May 7, 2013

CytRx Receives Recommendation from Data Safety Monitoring Committee to omplete International Phase 2b Trial with Aldoxorubicin - Benzinga

May 6, 2013

UPDATE: Edison Investment Research Raises PT on CytRx on FDA Aldoxorubicin Agreement - Benzinga

Apr 25, 2013

CytRx Announces Agreement with FDA on Special Protocol Assessment for Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin for Soft Tissue Sarcoma - Benzinga

Apr 23, 2013

5 Stocks Poised for Breakouts - TheStreet.com

Apr 19, 2013

See All News Stories on CYTR

Broker Recommendations

Current ABR	1.00
ABR (Last Week)	1.00
# of recs in ABR	2
Average Target Price	9.00
Industry Rank by ABR	96 out of 265
Rank in Industry	4 out of 157

More CYTR Broker Recommendations

Username: Password:

Remember me [?]

Forgot Password

New Member